Acknowledgement
This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (Ministry of Science, ICT and Future Planning; 2017R1A2B3005714, 2017R1C-1B2006193, 2020R1A5A2017476).
References
- Axelsen, T.M. and Woldbye, D.P.D. (2018). Gene therapy for Parkinson's disease, an update. J. Parkinsons Dis. 8, 195-215. https://doi.org/10.3233/JPD-181331
- Bjorklund, T. and Kordower, J.H. (2010). Gene therapy for Parkinson's disease. Mov. Disord. 25 Suppl 1, S161-S173. https://doi.org/10.1002/mds.22785
- Dauer, W. and Przedborski, S. (2003). Parkinson's disease: mechanisms and models. Neuron 39, 889-909. https://doi.org/10.1016/S0896-6273(03)00568-3
- Denyer, R. and Douglas, M.R. (2012). Gene therapy for Parkinson's disease. Parkinsons Dis. 2012, 757305.
- Ghee, M., Baker, H., Miller, J.C., Ziff, E.B. (1998). AP-1, CREB and CBP transcription factors differentially regulate the tyrosine hydroxylase gene. Brain Res. Mol. Brain Res. 55, 101-114. https://doi.org/10.1016/S0169-328X(97)00370-7
- Haycock, J.W. and Haycock, D.A. (1991). Tyrosine hydroxylase in rat brain dopaminergic nerve terminals. Multiple-site phosphorylation in vivo and in synaptosomes. J. Biol. Chem. 266, 5650-5657. https://doi.org/10.1016/S0021-9258(19)67644-1
- Kim, T.E., Park, M.J., Choi, E.J., Lee, H.S., Lee, S.H., Yoon, S.H., Oh, C.K., Lee, B.J., Kim, S.U., Lee, Y.S., et al. (2003). Cloning and cell type-specific regulation of the human tyrosine hydroxylase gene promoter. Biochem. Biophys. Res. Commun. 312, 1123-1131. https://doi.org/10.1016/j.bbrc.2003.11.029
- Marsden, C.D. (1990). Parkinson's disease. Lancet 335, 948-952. https://doi.org/10.1016/0140-6736(90)91006-V
- Mones, R.J., Elizan, T.S., Siegel, G. (1970). L-dopa induced dyskinesias in 152 patients with Parkinson's disease. Trans. Am. Neurol. Assoc. 95, 286-287.
- Nam, J.H., Park, E.S., Won, S.Y., Lee, Y.A., Kim, K.I., Jeong, J.Y., Baek, J.Y., Cho, E.J., Jin, M., Chung, Y.C., et al. (2015). TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF. Brain 138, 3610-3622. https://doi.org/10.1093/brain/awv297
- Park, M.H., Lee, H.S., Lee, C.S., You, S.T., Kim, D.J., Park, B.H., Kang, M.J., Heo, W.D., Shin, E.Y., Schwartz, M.A., et al. (2013). p21-Activated kinase 4 promotes prostate cancer progression through CREB. Oncogene 32, 2475-2482. https://doi.org/10.1038/onc.2012.255
- Piech-Dumas, K.M. and Tank, A.W. (1999). CREB mediates the cAMPresponsiveness of the tyrosine hydroxylase gene: use of an antisense RNA strategy to produce CREB-deficient PC12 cell lines. Brain Res. Mol. Brain Res. 70, 219-230. https://doi.org/10.1016/S0169-328X(99)00149-7
- Ramsey, A.J. and Fitzpatrick, P.F. (1998). Effects of phosphorylation of serine 40 of tyrosine hydroxylase on binding of catecholamines: evidence for a novel regulatory mechanism. Biochemistry 37, 8980-8986. https://doi.org/10.1021/bi980582l
- Rennefahrt, U.E., Deacon, S.W., Parker, S.A., Devarajan, K., Beeser, A., Chernoff, J., Knapp, S., Turk, B.E., Peterson, J.R. (2007). Specificity profiling of Pak kinases allows identification of novel phosphorylation sites. J. Biol. Chem. 282, 15667-15678. https://doi.org/10.1074/jbc.M700253200
- Tekin, I., Roskoski, R., Jr., Carkaci-Salli, N., Vrana, K.E. (2014). Complex molecular regulation of tyrosine hydroxylase. J. Neural Transm. (Vienna) 121, 1451-1481. https://doi.org/10.1007/s00702-014-1238-7
- Won, S.Y., Park, J.J., Shin, E.Y., Kim, E.G. (2019). PAK4 signaling in health and disease: defining the PAK4-CREB axis. Exp. Mol. Med. 12, 1-9.
- Won, S.Y., Park, M.H., You, S.T., Choi, S.W., Kim, H.K., McLean, C., Bae, S.C., Kim, S.R., Jin, B.K., Lee, K.H., et al. (2016). Nigral dopaminergic PAK4 prevents neurodegeneration in rat models of Parkinson's disease. Sci. Transl. Med. 8, 367ra170. https://doi.org/10.1126/scitranslmed.aaf1629
- Wood, H. (2020). Gene therapy boosts response to levodopa in patients with Parkinson disease. Nat. Rev. Neurol. 16, 242.
- Yun, C.Y., You, S.T., Kim, J.H., Chung, J.H., Han, S.B., Shin, E.Y., Kim, E.G. (2015). p21-Activated kinase 4 critically regulates melanogenesis via activation of the CREB/MITF and β-catenin/MITF pathways. J. Invest. Dermatol. 135, 1385-1394. https://doi.org/10.1038/jid.2014.548
- Zhu, Y., Zhang, J., Zeng, Y. (2012). Overview of tyrosine hydroxylase in Parkinson's disease. CNS Neurol. Disord. Drug Targets 11, 350-358. https://doi.org/10.2174/187152712800792901